FDG PET/CT in oncology: "raising the bar".
Integrated positron-emission tomography/computed tomography (PET/CT) with 2-[(18)F]-fluoro-2-deoxy-D-glucose (FDG) has revolutionized oncological imaging in recent years and now has a firmly established role in a variety of tumour types. There have been simultaneous step-wise advances in scanner technology, which are yet to be exploited to their full potential in clinical practice. This article will review these technological developments and explore how refinements in imaging protocols can further improve the accuracy and efficacy of PET/CT in oncology. The promises, and limitations, of emerging oncological applications of FDG PET/CT in radiotherapy planning and therapy response assessment will be explored. Potential future developments, including the use of FDG PET probes in oncological surgery, advanced data analysis techniques, and the prospect of integrated PET/magnetic resonance imaging (PET/MRI) will be highlighted.
Patel
C N
CN
Department of Radiology, Churchill Hospital, Oxford Radcliffe NHS Trust, Oxford, UK.
Goldstone
A R
AR
Chowdhury
F U
FU
Scarsbrook
A F
AF
D019788:Fluorodeoxyglucose F18; D006801:Humans; D009367:Neoplasm Staging; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy; D049268:Positron-Emission Tomography / Q000592:standards* / Q000639:trends; D017410:Practice Guidelines as Topic; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed / Q000592:standards* / Q000639:trends; D006113:United Kingdom
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18